Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Sep 05, 2018 11:16am
119 Views
Post# 28565445

RE:Production capacity -Wuxi

RE:Production capacity -Wuxi
palinc2000 wrote: Is there hard evidence to really know how many patients can be treated out of the existing facilities?


Its relatively easy to workout potential production capacity of monoclonal antibodies with some wobble.

The basic number is protein yield per litre. We dont know the specific yield for trogarzo but most antibodies fall within a yield range of 1-5g/litre

Cell cultures take two weeks, so a single bioreactor can theoretically handle 26 batch runs per year.

Trogarzo is produced in 2000l bioreactors and I believe Wuxi have 20 2000l bioreactor but they have been constantly expanding their capacity over the past couple of years.

When I crunched the numbers it looked to me that one 2000l bioreactor LIKELY covers 1500 patients if it solely was used to produce Trogarzo.

Its unlikely that Wuxi's ABSOLUTE capacity is 1500 patients but its possible that the contract between Wuxi and Taimed only covers that amount.

The short answer to your question : no I have no hard evidence.

Bullboard Posts